The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Papers of special note have been highlighted as: •• of considerable interest

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J. Hepatocell. Carcinoma 4, 81–92 (2017).
  MedlineGoogle Scholar
• 3. Lau WY, Leung TW, Lai BS et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann. Surg. 233(2), 236–241 (2001).
  Medline CASGoogle Scholar
• 4. Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1), 358–380 (2018).
  MedlineGoogle Scholar
• 5. Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular carcinoma: an overview of the changing landscape of treatment options. J. Hepatocell. Carcinoma 8, 387–401 (2021).
  MedlineGoogle Scholar
• 6. Llovet JM, Kelley RK, Villanueva A et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7(1), 6 (2021).
  MedlineGoogle Scholar
• 7. Ohki T, Sato K, Kondo M et al. Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma. Liver Res. 4(4), 199–205 (2020).
  Google Scholar
• 8. Atallah E, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica 105(12), 2738–2745 (2020).
  Medline CASGoogle Scholar
• 9. Zou X-L, Li X-B, Ke H et al. Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer. Front. Immunol. 12, (2021).
  Google Scholar
• 10. Mauriello A, Zeuli R, Cavalluzzo B et al. High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients not undergoing immunotherapy. Cancers 11(12), 1824 (2019).
  Medline CASGoogle Scholar
• 11. Wong M, Kim JT, Cox B et al. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. Hepat. Oncol. 8(4), HEP39–HEP39 (2021).
  Google Scholar
• 12. Federico P, Petrillo A, Giordano P et al. Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives. Cancers 12(10), (2020).
  Google Scholar
• 13. Yau T, Kang Y-K, Kim T-Y et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol. 6(11), e204564–e204564 (2020).
  MedlineGoogle Scholar
• 14. Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19(7), 940–952 (2018).
  MedlineGoogle Scholar
• 15. Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905 (2020). •• A pivotal, positive phase III study with immunotherapy changing the treatment algorithms in advanced hepatocellular carcinoma (HCC).
  Medline CASGoogle Scholar
• 16. Abou-Alfa GK, Lau G, Kudo M et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1(8), EVIDoa2100070 (2022). •• The first positive phase III study using an immunotherapy-immunotherapy combination in the first-line treatment of advanced HCC.
  MedlineGoogle Scholar
• 17. Yau T, Park J-W, Finn RS et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 23(1), 77–90 (2022).
  Medline CASGoogle Scholar
• 18. Teng W, Lin CC, Ho MM et al. Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. Am. J. Cancer Res. 11(5), 2319–2330 (2021).
  Medline CASGoogle Scholar
• 19. Hsu WF, Chuang PH, Chen CK et al. Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience. Am. J. Cancer Res. 10(12), 4547–4560 (2020).
  Medline CASGoogle Scholar
• 20. Kelley RK, Rimassa L, Cheng A-L et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 23(8), 995–1008 (2022).
  Medline CASGoogle Scholar
• 21. Ren Z, Xu J, Bai Y et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 22(7), 977–990 (2021).
  Medline CASGoogle Scholar
• 22. Cheng A-L, Qin S, Ikeda M et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. doi: 10.1016/j.jhep.2021.11.030 (2022).
  Google Scholar
• 23. Haber PK, Puigvehí M, Castet F et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). Gastroenterology 161(3), 879–898 (2021). •• A fundamental meta-analysis evaluating the treatment landscape of HCC across two decades.
  Medline CASGoogle Scholar
• 24. Pfister D, Núñez NG, Pinyol R et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592(7854), 450–456 (2021). •• A pivotal study investigating the mechanisms of immunotherapy underperformance in nonviral HCC.
  Medline CASGoogle Scholar
• 25. Ho WJ, Danilova L, Lim SJ et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J. Immunother. Cancer 8(1), e000394 (2020).
  MedlineGoogle Scholar
• 26. Ding Z, Dong Z, Chen Z et al. Viral status and efficacy of immunotherapy in hepatocellular carcinoma: a systematic review with meta-analysis. Front. Immunol. 12, 733530 (2021).
  Medline CASGoogle Scholar
• 27. Page MJ, Mckenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
  MedlineGoogle Scholar
• 28. Qin S, Chen Z, Fang W et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J. Clin. Oncol. 40(Suppl. 4), 383–383 (2022).
  Google Scholar
• 29. Finn RS, Ryoo BY, Merle P et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38(3), 193–202 (2020).
  Medline CASGoogle Scholar
• 30. Finn R, Kudo M, Merle P et al. LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann. Oncol. 33, S1401 (2022).
  Google Scholar
• 31. Qin S, Kudo M, Meyer T et al. LBA36 Final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann. Oncol. 33, S1402–S1403 (2022).
  Google Scholar
• 32. Qin S, Chan L, Gu S et al. LBA35 camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann. Oncol. 33, S1401–S1402 (2022). •• The first positive phase III study using an immunotherapy-tyrosine-kinase inhibitor combination in the first-line treatment of advanced HCC.
  Google Scholar
• 33. Ho WJ, Danilova L, Lim SJ et al. Viral status,immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J. Immunother. Cancer 8(1), e000394 (2020).
  MedlineGoogle Scholar
• 34. Ding Z, Dong Z, Chen Z et al. Viral status and efficacy of immunotherapy in hepatocellular carcinoma: a systematic review with meta-analysis. Front Immunol. 12, 733530 (2021).
  Medline CASGoogle Scholar
• 35. Cabibbo G, Celsa C, Enea M et al. Progression-free survival early assessment is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma. Cancers 13(1), 90 (2020).
  MedlineGoogle Scholar
• 36. Nakano M, Yatsuhashi H, Bekki S et al. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci. Rep. 12(1), 1517 (2022).
  Medline CASGoogle Scholar
• 37. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156(2), 477–491.e471 (2019).
  MedlineGoogle Scholar
• 38. Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Int. J. Oncol. 43(5), 1333–1342 (2013).
  Medline CASGoogle Scholar
• 39. Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J. Hepatol. 5(6), 311–322 (2013).
  MedlineGoogle Scholar
• 40. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 16(29), 3603–3615 (2010).
  MedlineGoogle Scholar
• 41. Karin M. New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis. Clin. Med. 1(1), 21–28 (2018).
  MedlineGoogle Scholar
• 42. Orci LA, Sanduzzi-Zamparelli M, Caballol B et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin. Gastroenterol. Hepatol. 20(2), 283–292.e210 (2022).
  MedlineGoogle Scholar
• 43. Mak LY, Cruz-Ramón V, Chinchilla-López P et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am. Soc. Clin. Oncol. Educ. Book 38, 262–279 (2018).
  MedlineGoogle Scholar
• 44. Song G, Shi Y, Zhang M et al. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov. 6(1), 90 (2020).
  Medline CASGoogle Scholar
• 45. Borgia M, Dal Bo M, Toffoli G. Role of virus-related chronic inflammation and mechanisms of cancer immune-suppression in pathogenesis and progression of hepatocellular carcinoma. Cancers (Basel) 13(17), (2021).
  Google Scholar
• 46. Bonilla CM, Mcgrath NA, Fu J, Xie C. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Res. 6, 68 (2020).
  MedlineGoogle Scholar
• 47. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19(2), 156–172 (2009).
  Medline CASGoogle Scholar
• 48. Saito T, Ichimura Y, Taguchi K et al. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat. Commun. 7, 12030 (2016).
  Medline CASGoogle Scholar
• 49. Seike T, Mizukoshi E, Yamada K et al. Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. J. Gastroenterol. 55(7), 701–711 (2020).
  Medline CASGoogle Scholar
• 50. Inada Y, Mizukoshi E, Seike T et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology 69(2), 653–665 (2019).
  Medline CASGoogle Scholar
• 51. Yarchoan M, Xing D, Luan L et al. Characterization of the immune microenvironment in hepatocellular carcinoma. Clin. Cancer Res. 23(23), 7333–7339 (2017).
  Medline CASGoogle Scholar
• 52. Lim CJ, Lee YH, Pan L et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut 68(5), 916–927 (2019).
  Medline CASGoogle Scholar
• 53. Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl. Gastroenterol. Hepatol. 4, 72 (2019).
  MedlineGoogle Scholar
• 54. Cariani E, Missale G. Immune landscape of hepatocellular carcinoma microenvironment: implications for prognosis and therapeutic applications. Liver Int. 39(9), 1608–1621 (2019).
  MedlineGoogle Scholar
• 55. De Battista D, Zamboni F, Gerstein H et al. Molecular signature and immune landscape of HCV-associated hepatocellular carcinoma (HCC): differences and similarities with HBV-HCC. J. Hepatocell. Carcinoma 8, 1399–1413 (2021).
  MedlineGoogle Scholar
• 56. Mee CJ, Farquhar MJ, Harris HJ et al. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 138(3), 1134–1142 (2010).
  Medline CASGoogle Scholar
• 57. Zhu C, Liu X, Wang S et al. Hepatitis C virus core protein induces hypoxia-inducible factor 1α-mediated vascular endothelial growth factor expression in Huh7.5.1 cells. Mol. Med. Rep. 9(5), 2010–2014 (2014).
  Medline CASGoogle Scholar
• 58. Alzamzamy A, Elsayed H, Abd Elraouf M, Eltoukhy H, Megahed T, Aboubakr A. Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients. World J. Gastrointest. Oncol. 13(6), 600–611 (2021).
  MedlineGoogle Scholar
• 59. Villani R, Facciorusso A, Bellanti F et al. DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment. PLOS ONE 11(12), e0167934 (2016).
  MedlineGoogle Scholar
• 60. Faillaci F, Marzi L, Critelli R et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology 68(3), 1010–1024 (2018).
  Medline CASGoogle Scholar
• 61. Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J. Hepatol. 67(5), 999–1008 (2017).
  Medline CASGoogle Scholar
• 62. Bruix J, Raoul J-L, Sherman M et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J. Hepatol. 57(4), 821–829 (2012).
  Medline CASGoogle Scholar
• 63. Papatheodoridis GV, Chan HL-Y, Hansen BE, Janssen HLA, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J. Hepatol. 62(4), 956–967 (2015).
  MedlineGoogle Scholar
• 64. Lebossé F, Gudd C, Tunc E et al. CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine 49, 258–268 (2019).
  Medline CASGoogle Scholar
• 65. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. 61(6), 1385–1396 (2014).
  Medline CASGoogle Scholar
• 66. Kaseb AO, Hasanov E, Cao HST et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7(3), 208–218 (2022).
  MedlineGoogle Scholar
• 67. Marron TU, Fiel MI, Hamon P et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7(3), 219–229 (2022).
  MedlineGoogle Scholar
• 68. Chen GH, Wang GB, Huang F et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl. Immunol. 66, 101386 (2021).
  Medline CASGoogle Scholar
• 69. Dehghan Y, Schnickel GT, Hosseini M et al. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clin. J. Gastroenterol. 14(6), 1718–1724 (2021).
  MedlineGoogle Scholar
• 70. Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am. J. Transplant. 21(5), 1979–1980 (2021).
  Medline CASGoogle Scholar
• 71. Sogbe M, López-Guerra D, Blanco-Fernández G, Sangro B, Narváez-Rodriguez I. Durvalumab as a successful downstaging therapy for liver transplantation in hepatocellular carcinoma: the importance of a washout period. Transplantation 105(12), 398–400 (2021).
  Google Scholar
• 72. Llovet JM, Castet F, Heikenwalder M et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19(3), 151–172 (2022).
  Medline CASGoogle Scholar
• 73. Shimada S, Mogushi K, Akiyama Y et al. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine 40, 457–470 (2019). •• A landmark study evaluating the molecular landscape of HCC with implications for treatment selection.
  MedlineGoogle Scholar
• 74. Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune-oncology in hepatocellular carcinoma. Int. J. Clin. Oncol. 27(7), 1101–1109 (2022).
  Medline CASGoogle Scholar
• 75. Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J. Hepatol. 71(3), 616–630 (2019).
  Medline CASGoogle Scholar
• 76. Rebouissou S, Franconi A, Calderaro J et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology 64(6), 2047–2061 (2016).
  Medline CASGoogle Scholar
• 77. Chen L, Zhou Q, Liu J, Zhang W. CTNNB1 alternation is a potential biomarker for immunotherapy prognosis in patients with hepatocellular carcinoma. Front. Immunol. 12, 759565 (2021).
  Medline CASGoogle Scholar
• 78. Zhu AX, Abbas AR, De Galarreta MR et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28(8), 1599–1611 (2022).
  Medline CASGoogle Scholar
• 79. Sia D, Jiao Y, Martinez-Quetglas I et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 153(3), 812–826 (2017).
  Medline CASGoogle Scholar
• 80. Sangro B, Melero I, Wadhawan S et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J. Hepatol. 73(6), 1460–1469 (2020).
  Medline CASGoogle Scholar